Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06286033 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study and Food Effect Study for AG181
A Phase 1 study, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT06286033 is a Phase 1 study that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 88 participants.
The verdict
NCT06286033, a Phase 1 study, has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the safety and tolerability of AG-181 in healthy participants after oral administration of single ascending dose (SAD) of AG-181 in Part 1 and multiple ascending dose (MAD) in Part 2 along with the effect of food on the pharmacokinetics (PK) of single oral doses of AG-181 in healthy participants in Part 3.
Interventions
- DRUG Placebo
- DRUG AG-181
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2025-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06286033
The ClinicalTrials.gov registry entry for NCT06286033 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06286033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06286033 about?
NCT06286033 is a clinical study titled "Single and Multiple Ascending Dose Study and Food Effect Study for AG181". The primary purpose of this study is to assess the safety and tolerability of AG-181 in healthy participants after oral administration of single ascending dose (SAD) of AG-181 in Part 1 and multiple ascending dose (MAD) in Part 2 along with the effect of food on the pharmacokinetics (PK) of single o...
What is the current status of trial NCT06286033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2024-02-20. Estimated completion is 2025-10-09.
What interventions are being tested in trial NCT06286033?
The interventions under investigation include: Placebo (DRUG), AG-181 (DRUG).
Who is sponsoring clinical trial NCT06286033?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.